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Objective: Management of lower extremity arterial disease with endovascular intervention is on the rise. Current practice
patterns vary widely across and within specialty practices that perform endovascular intervention. This study evaluated
reimbursement and costs of different approaches for offering endovascular intervention and identified strategies to
improve cost-efficiency.
Methods: The medical records of all patients admitted to a university health system during 2005 for an endovascular
intervention were retrospectively reviewed. Procedure type, setting, admission status, and financial data were recorded.
Groups were compared using analysis of variance, Student t test for independent samples, and 2.
Results: A total of 296 endovascular interventions were completed, and 184 (62%) met inclusion criteria. Atherectomy
and stenting were significantly more costly when performed in the operating room than in the radiology suite:
atherectomy, $6596 vs $4867 (P  .002); stent, $5884 vs $3292, (P < .001); angioplasty, $2251 vs $1881 (P  .46).
Reimbursement was significantly higher for inpatient vs ambulatory admissions (P < .001). Costs were lowest when the
endovascular intervention was done in the radiology suite on an ambulatory basis and highest when done as an inpatient
in the operating room ($5714 vs $12,278; P < .001). Contribution margins were significantly higher for inpatients. Net
profit was appreciated only for interventions done as an inpatient in the radiology suite. Reimbursement, contribution
margins, and net profit were significantly lower among private pay patients in both the ambulatory and inpatient setting.
The 30-day hospital readmission after ambulatory procedures was seven patients (6%).
Conclusions: Practice patterns for endovascular interventions differ considerably. Costs vary by procedure and setting, and
reimbursement depends on admission status and accurate documentation; these dynamics affect affordability. Organizing
vascular services within a hub will ensure that care is delivered in the most cost-efficient manner. Guidelines may include
designating the radiology suite as the primary venue for endovascular interventions because it is less costly than the
operating room. Selective stenting policies should be considered. Contracts with private insurers must include carve-outs
for stent costs and commensurate reimbursement for ambulatory procedures, and Current Procedural Terminology
(CPT; American Medical Association, Chicago, Ill) coding must be proficient to make ambulatory endovascular
interventions fiscally acceptable. ( J Vasc Surg 2008;47:982-7.)Endovascular intervention (EVI) has revolutionized
the management of peripheral vascular disease (PVD). Al-
though optimal treatment strategies remain undetermined
at this time, previous studies have reported improved clin-
ical outcomes after EVI for treatment of disabling claudi-
cation and critical ischemia.1 Some authors have reported
that EVI is less costly than conventional open repair in the
treatment of PVD,2,3 but prevailing concerns about the
expense of this new technology have prompted investiga-
tors to examine the efficiency of current EVI strategies.
Greenburg et al4 reported that primary stenting did not
significantly improve clinical outcome but significantly in-
creased the initial cost of treatment and consequently rec-
ommended selective or provisional stenting policies. Still
others have supported selective stenting on the basis that
long-term costs will be reduced owing to lower failure rates
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982than with angioplasty alone.5 Investigations on the efficacy
and cost-effectiveness of EVI as an ambulatory procedure
concluded that EVI can be completed safely as an ambula-
tory procedure and at lower cost.6,7
Endovascular interventions are performed by several
practitioners in a variety of specialty areas resulting in broad
diversification of clinical practice that may not always be the
most cost-efficient or affordable. Costs of EVI differ by
procedure and also fluctuate among the settings in which it
is performed. Admission status will also affect reimburse-
ment. Reductions in cost alone may not necessarily lead to
care that is more affordable, but rather, cost and reimburse-
ment must be examined in tandem to develop a fiscally
solvent plan. This study was designed to examine reim-
bursement and costs of EVI in effort to identify strategies
that may be implemented to provide EVI in the most
cost-efficient, affordable manner.
METHODS
A retrospective review was undertaken of all lower
extremity EVI completed within two adult acute-care hos-
pitals of a consolidated, university-affiliated tertiary care
health system during 2005. The health system’s database
(Trend Star) was queried for the following International
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tion (ICD-9-CM) procedure codes:
● 39.50—angioplasty or atherectomy, non-coronary
vessels, other;
● 39.90—insertion of a nondrug-eluting peripheral vas-
cular stent;
● 00.45—insertion of one vascular stent;
● 00.46—insertion of two vascular stents;
● 00.47—insertion of three vascular stents; and
● 00.48—insertion of four or more vascular stents.
All cases were reviewed to identify lower extremity
EVIs. Additional screening was used to limit the data set to
patients who were admitted exclusively for the treatment of
PVD with an EVI because it was necessary to create a
homogeneous sample in effort to accurately capture costs
and facilitate financial analysis. Exclusion criteria included
concomitant lytic therapy, multiple trips to the operating
room or radiology suite, combined EVI and open proce-
dure, procedure completed 3 days after admission, or
length of stay 5 days.
The following variables were recorded:
● procedure classification—stent, atherectomy, or bal-
loon angioplasty;
● procedure setting—radiology suite (RS) or operating
room (OR);
● admission status—inpatient, ambulatory (patients ad-
mitted with the intention of being discharged the same
day), or ambulatory overnight (patients admitted on
an ambulatory basis but who remained hospitalized
overnight);
● indication for the EVI—claudication, rest pain, non-
healing ulcer, or gangrene;
● distal vessel treated; and
● postoperative morbidity and mortality.
Financial data were obtained from the health system’s
department of finance. The health system uses ledger-based
accounting to compile costs. Direct costs are calculated by
assembling costs of consumables as well as “cost per unit
time of room use,” which includes direct, fixed equipment
costs and personnel salaries. Indirect hospital costs include
variables such as utilities, building and maintenance, mort-
gages, personnel fringe benefits, malpractice insurance, and
administrative salaries and fringe benefits.
The contribution margin is a financial variable that is
often used by hospital administrators to evaluate the pro-
ductivity or profitability of a procedure and is calculated by
subtracting hospital direct costs from reimbursement. In-
direct costs are excluded from the formula because they
represent “fixed costs” that would be incurred by the
hospital regardless of whether the procedure was per-
formed. The variables recorded were reimbursement; direct
procedural costs including costs of personnel to staff the
room, costs of stents and atherectomy catheters, and costs
of other consumable medical supplies; direct, indirect, and
total cost of hospitalization; contribution margin, and hos-
pital net gain/loss. Provider information was recorded andcategorized as Medicare or private pay. Statistical analysis
was performed using SPSS 14.0 software (SPSS Inc, Chi-
cago Ill). Groups were compared using analysis of variance,
Student t test for independent samples, and 2. Statistical
significance was established at P  .05.
RESULTS
During 2005, 296 EVI procedures were performed at
the health center. Of these, 112 (38%) were excluded
because 39 (13%) had a length of stay 5 days or the
procedure was completed 3 days after admission, 31
(11%) had concomitant lytic therapy, 24 (8%) had com-
bined open procedures, 12 (4%) had multiple trips to the
operating room, and 6 (2%) had incomplete financial data.
The effective sample size was 184 (62%).
Vascular surgeons performed 84% of cases at two of the
four adult care hospitals. Significant variation in practice
between hospitals was noted. Cases were completed nearly
exclusively in the OR at one hospital and performed nearly
exclusively in the RS at the other hospital. Procedures were
completed on an inpatient basis in 71 patients (39%), and
113 (61%) were as ambulatory procedures. Significant vari-
ation in admission status occurred between hospitals. At
the hospital in which EVIs are performed in the OR, 54% of
procedures were done on an inpatient basis in contrast to
24% at the hospital in which EVIs are performed in the RS
(P  .001).
The indication for the EVI was claudication (49%), rest
pain (16%), nonhealing ulcer (29%), and gangrene (6%).
The indication of claudication vs critical limb ischemia for
the EVI did not differ significantly by setting, admission
status, surgeon, or hospital. Themost common type of EVI
performed was stenting (45%), followed by atherectomy
(38%) and angioplasty (17%). One to five vessels were
treated per procedure, although treatment of one vessel was
most common (56%). Themost distal vessel treated was the
iliac artery (28%), common femoral artery/superficial fem-
oral artery (30%), above knee/below knee popliteal (21%),
and distal to the trifurcation (21%). No deaths or major
cardiac morbidity occurred after the EVIs. Hematoma oc-
curred in 2.7% of ambulatory patients and 2.8% of inpa-
tients.
Direct procedural costs are an aggregation of personnel
costs computed by unit time of room use in addition to
the cost of consumable medical supplies. The direct proce-
dural costs of angioplasty ($1967) were significantly less
than stenting ($5105) or atherectomy ($5081; P  .001).
Both stenting and atherectomy were significantly more
expensive when performed in the OR than in the RS.
Personnel costs and costs of miscellaneous medical supplies
were $1886 higher for atherectomy (P .001) and $1124
for stenting (P .001). The costs of atherectomy catheters
between locations were not significant; however, costs of
stents were higher in the OR, but this difference became
statistically insignificant ($270) when multiple stents were
excluded (Table I). Although costs of performing angio-
plasty were higher in the OR ($2251) than in the RS
placed
JOURNAL OF VASCULAR SURGERY
May 2008984 O’Brien-Irr et al($1881), the difference was not statistically significant. The
low number of angioplasties completed in theORmay have
been insufficient to establish significance.
Multiple stents were placed in 35 cases (42%), with the
most common practice being two stents per case (range,
2-5 stents). Direct procedural costs ($6597 vs $4223; P 
.002) and net loss ($3344 vs $1216; P  .027) were
significantly higher when multiple stents were placed com-
pared with a single stent. Unfortunately, subgroup analysis
for multistent placement in single vs multiple vessels was
not possible owing to the limited subgroup size and lack of
homogeneity in admission status and procedure location,
both of which affect cost and reimbursement.
Total hospital costs were significantly lower for ambu-
latory procedures than for those completed on an inpatient
basis ($6343 vs $10,582, P  .001). Direct costs of the
procedure and direct hospital costs were lowest for ambu-
latory procedures completed in the RS and highest for
inpatient procedures completed in the OR.
Reimbursement was significantly higher when the EVI
was completed on an inpatient basis vs an ambulatory
Table I. Costs of atherectomy and stenting by setting
Variable
Atherectomya
OR RS
Stent/atherectomy device $3319  $303 $3476 
Personnel, other medical supplies $3277  $301 $1391 
Total room costs $6596  $383 $4867 
OR, Operating room; RS, radiology suite.
aData are presented as the mean  standard error of the mean.
bThere was no significant difference in cost ($270) when a single stent was
Table II. Financial variables by admission status and proc
Procedure
setting No.
Procedurea
Direct cost Direct cost Indirec
In-patent
RS 24 $4169  $584 $5089  $600 $2243 
OR 47 $6593  $457 $7861  $467 $4417 
Ambulatory
RS 75 $3122  $191 $3572  $197 $2142 
OR 38 $5109  $511 $5572  $523 $2019 
P .001 .001 .00
OR, Operating room; RS, radiology suite.
aData are presented as the mean  standard error of the mean.
Table III. Contribution margin and net profit by insurer
Inpatienta
Medicare Private pay
Contribution margin $6126  $682 $2429  $101
Net profit $2791  $758 $1738  $129
aData are presented as the mean  standard error of the mean.procedure (P  .001). Contribution margins were signifi-cantly lower in ambulatory patients than in inpatients and
directly reflected lower reimbursement rates associated
with ambulatory admissions. Profit was appreciated only for
inpatients whose procedures were completed in the RS
because of higher inpatient reimbursement and lower RS
costs. Loss occurred in all other designations but was
greatest in ambulatory patients whose procedures were
completed in the OR. Again, this was due to the higher
costs linked to the OR as well as to lower reimbursement
rates for ambulatory admissions (Table II). Reimburse-
ment, contribution margin, and net profit were signifi-
cantly lower among patients who had private insurance
compared with Medicare patients in both the ambulatory
and inpatient settings (Table III).
Subgroup analysis of all excluded cases was completed.
Total hospital costs were lytic therapy, $15,624; multiple
trips to the OR, $14,615; multiple trips to the RS,
$11,415; and patients whose procedures occurred3 days
after admission or a length of stay 5 days, $13,481. The
average net gain for all excluded cases was $3012, but loss
occurred in patients receiving lytic therapy ($479) and in
P
Stenta
POR RS
7 NS $3097b  $323 $1729b  $165 .001a
3 .001 $2787  $197 $1663  $268 .001
2 .002 $5884  $462 $3392  $280 .001
.
setting by analysis of variance
Hospital variablesa
Total cost Contribution margin Net profit
2 $7331  $764 $7720  $789 $5464  $735
2 $12,278  $595 $3114  $716 $1317  $839
6 $5714  $245 $267  $281 $1876  $336
8 $7591  $616 $678  $434 $2697  $502
.001 .001 .001
dmission status
P
Ambulatorya
PMedicare Private pay
.003 $1173  $322 $812  $306 .001
.002 $779  $361 $3070  $379 .001$30
$17
$35edure
t cost
$43
$19
$12
$10
1and a
5
0those requiring multiple trips to the OR ($1586).
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ambulatory basis. Endovascular intervention as an ambula-
tory procedure was done at the discretion of the admitting
physician because there was no existing pathway to guide
triage. Twenty-nine ambulatory patients (26%) remained
overnight at an additional cost of $407.00, which was not
statistically significant (P  .53). Reimbursement did not
differ significantly for patients with ambulatory overnight
procedures compared with patients discharged the same
day but was significantly lower for ambulatory overnight
procedures than for inpatient procedures (P .001). These
findings occurred for EVI procedures overall and within
each category of EVI individually, indicating that ambula-
tory overnight admissions were not reimbursed at the in-
patient level but rather at the ambulatory rate. Six over-
night stays (5%) were for postprocedurally related issues.
Seven patients (5%) were readmitted30 days of discharge
for EVI-related problems.
DISCUSSION
Endovascular intervention for the treatment of PVD
has increased tremendously during the past decade. Costs
and benefits of any new technology must be carefully
evaluated before widespread use. Numerous studies have
evaluated clinical outcomes after EVI but fewer have fo-
cused on costs. Endovascular intervention is currently
performed by a variety of physicians in several different
specialty practices; consequently, significant variation in
clinical practice exists. The lack of a standardized approach
for offering an EVI can lead to cost inefficiency. We found
substantial dissimilarities within our own health system that
provided unique opportunity to examine the costs and
reimbursement of different strategies for offering EVI. It is
crucial that physicians who perform EVIs become knowl-
edgeable of cost and reimbursement dynamics so that they
may partner with hospital administrators to examine EVI
practices and effect appropriate change. Organization of
vascular services will ensure that care will be delivered in the
most affordable manner.
Recently, d’Othee et al8 reported that the comprehen-
sive cost for placement of an arterial stent was $2780. We
found that the direct procedural cost for stent placement in
the RS was $3392 and was significantly higher ($2492)
when the procedure was completed in the OR ($5844).
Increased cost of personnel and greater use of miscellaneous
consumable medical supplies raised OR costs by $1124. Al-
though costs of the stent(s) were higher in theOR than in the
RS and contributed $1368 to the net increase in costs, that
difference became statistically insignificant ($270) when mul-
tiple stents were excluded.
Similar findings were noted for atherectomy. Increased
costs of personnel and greater use of miscellaneous medical
supplies raised OR costs by $1886. The overall net differ-
ence was $1729 because of slightly higher cost in the RS
due to differences in the use of Excimer (Spectranetics
Corporation, Colorado Springs, Colo) or SilverHawk
(FoxHollow Technologies Inc, Redwood City, Calif) cath-
eters. Costs of performing angioplasty in theORwere $370higher than in the RS, although this difference was not
statistically significant.
Designating the RS as the primary venue for percuta-
neous EVIs for all practitioners should be considered.
Reserving the OR for cases in which hybrid procedures are
anticipated will facilitatemore efficient use of this costly and
highly used resource. Hospital administrators should avoid
entering into exclusive contracts with any particular spe-
cialty practice that would limit access by others to the RS.
Previous investigators have recommended provisional
stenting policies.4,5 We noted that angioplasty was signifi-
cantly less expensive than stenting or atherectomy and,
therefore from a fiscal standpoint, support a provisional
stenting policy until randomized clinical trials recommend
global stenting or atherectomy rather than angioplasty
alone. Policies that reserve atherectomy and stenting for
patients who are not amenable to angioplasty from an
anatomic standpoint or to those in which suboptimal results
were achievedwith angioplasty alone should be considered. In
fact, coding regulations mandate documentation of subopti-
mal angioplasty results before stent implantation as a requisite
to receive maximal reimbursement.
We found that it was significantly more costly to place
multiple stents than a single stent, and hospital loss was
$2128 greater (P  .027) when multiple stents were
placed. Current coding guidelines allow for additional re-
imbursement whenmultiple stents are placed in contiguous
arteries but not within a single vessel. Unfortunately, our
sample size was insufficient to provide any meaningful
analysis for this. Nonetheless, because loss was significantly
greater when multiple stents were placed, contracts with
private payors may need to be restructured to include
carve-outs to cover the cost of each stent regardless of
anatomic placement.
Although EVI is still often performed as an inpatient
procedure, many physicians have already begun to perform
EVI on an ambulatory basis. The safety and efficacy as well
as the associated reduction in hospital charges associated
with this practice have been previously reported.6,7 Our
data concur with previous studies that EVI can be com-
pleted safely as an ambulatory procedure. Postoperative
mortality and morbidity rates were comparable with inpa-
tient procedures, and the 30-day hospital readmission rate
after ambulatory EVI was only 6%.
Of the patients admitted on an ambulatory basis, 26%
remained overnight but only six (5%) were for postproce-
durally related issues. The additional cost of $406.00 for
the overnight stay was not statistically significant. Many
physicians who perform EVIs may commonly mistake the
practice of scheduling and performing EVI as an ambula-
tory procedure and then admitting the patient overnight as
being financially advantageous for hospitals, when in fact, it
is not. We found that ambulatory overnight admissions
were not reimbursed at the inpatient level but rather at the
ambulatory rate; moreover, albeit nominal, additional over-
night costs were incurred.
Third-party payors and hospitals use accepted stan-
dards of care to establish the necessity of inpatient admis-
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qualified surgical procedure or specific severity of illness
and intensity of service criteria. According to the 2007
InterQual guidelines (McKesson Health Solutions, LLC,
Newton, Mass), angioplasty of peripheral vessels has been
designated as an appropriate inpatient procedure and criti-
cal limb ischemia as appropriate severity of illness criteria.9
Routine postprocedural care at our health center rarely met
InterQual “intensity of service” guidelines that would jus-
tify inpatient admission. This is particularly important in
the context of ambulatory overnight admissions and may
provide further explanation about why reimbursement was
provided at the ambulatory level. Our data suggest that
once the EVI is completed as an ambulatory procedure, the
designation of a “qualifying surgical procedure” alone is
insufficient to attain inpatient reimbursement for overnight
stays. Rather, inpatient reimbursement may be contingent
upon use of qualifying “intensity of service” criteria. In-
creased physician awareness regarding these reimburse-
ment schemes will be helpful.
We found that the ambulatory EVI was less expensive
than an inpatient ($6343 vs $10,582; P .001) EVI. Total
hospital costs were least expensive when EVI was per-
formed in the RS as an ambulatory procedure and most
expensive when completed as an inpatient in the OR
($5714 vs $12,278; P  .001). However, we also found
that total hospital costs for inpatient procedures completed
in the RS were comparable with ambulatory procedures
completed in the OR ($7331 vs $7591: P  .74). As a
consequence, any financial benefit attained from complet-
ing the EVI on an ambulatory basis may be offset if the
procedure is completed in the OR.
Contribution margins were significantly lower when
the EVI was performed as an ambulatory procedure and
directly reflected lower reimbursement rates designated for
ambulatory procedures. Moreover, we noted that profit
was appreciated only for EVI procedures completed on an
inpatient basis in the RS and that deficit occurred in every
other designation. Loss was greatest among ambulatory
patients whose procedures were completed in the OR
owing to the higher costs associated with that venue as well
as to lower reimbursement rates for ambulatory admission.
Reimbursement for ambulatory procedures is driven by
Current Procedural Terminology (CPT; AmericanMedical
Association, Chicago, Ill) codes with attached ambulatory
payment classification (APC) payment and consequently is
contingent on accurate documentation and coding of pro-
cedures. In contrast with inpatient admissions that are
reimbursed by the Diagnosis-Related Group (DRG) sys-
tem and for which there are only one or two ICD-9-CM
procedure codes, CPT coding for ambulatory EVI is com-
plex. Coding of individual components of each procedure is
mandated. Primary procedures are normally reimbursed at
100% of the APC payment, whereas each additional proce-
dure receives a reduced percentage. The task of accurate
coding has become increasingly difficult owing to the esca-
lating complexity of EVI procedures and demonstrates the
importance of clear concise documentation by physiciansand the need for coders who are extremely knowledgeable
of EVI regulations.
Loss occurred when EVI was performed on an ambu-
latory basis regardless of insurer but was significantly lower
for Medicare ($779) than for private payors ($3070).
Reimbursement by private insurers for ambulatory proce-
dures was by categories or groups of CPT codes. Additional
carve-outs for implantable devices were provided for, yet
reimbursement was clearly insufficient. Inpatient reim-
bursement by private payors was by DRG but did not
include an additional allotment for implantable devices.
Negotiation strategies with private payors must be carefully
evaluated. Contracts must include carve-outs for implant-
able devices and be structured towards attaining commen-
surate reimbursement for ambulatory procedures.
The Centers for Medicare and Medicaid implemented
reforms in August 2006 designed to overhaul current re-
imbursement schemes.10 The new tactic could potentially
shift Medicare reimbursement for EVI from inpatient to
ambulatory, making it more equitable to perform EVI on
this basis but also making proficient CPT coding increas-
ingly critical. Although private insurers usually follow suit,
renegotiation may still be necessary.
CONCLUSION
Many hospitals currently operate without standardized
protocols for offering EVIs. Our data provide a compelling
rationale for organizing vascular services within a “hub” to
foster collaborative practice and avoid varying protocols.
Creation of a vascular core would promote delivery of care
in the most cost-efficient and affordable manner. We have
provided guidelines that may be useful for protocol devel-
opment. It is crucial that physicians who perform EVIs be
knowledgeable of cost and reimbursement dynamics at
their own institutions so they may partner with administra-
tors to guide the development of vascular centers.
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O’Brien and associates have shown that hospital net profit for
lower extremity endovascular treatment (EVI) depends on: (1)
patient status—inpatient vs outpatient, (2) site of service deliv-
ery—operating room vs radiology suite, and (3) type of catheter-
based treatment—percutaneous balloon angioplasty (PTA), stents,
or atherectomy. Why are these observations on EVI, particularly of
the femoral-popliteal segment, important? Femoral-popliteal by-
pass has decreased by 6% over the last decade, and by 2009, it will
comprise only 30% of treatment for this segment.1,2 EVI, however,
is projected to increase by 27% by 2009 for the femoral popliteal
segment and represent 70% of treatment. This tectonic shift in
treatment will greatly affect one of a hospital’s top three sources of
revenue and contribution margin—the vascular service.
Although profound differences in practice patterns were de-
scribed among the hospitals studied, their system, cost and revenue
data was lumped together as mean values. One hospital performed
EVI predominantly in the operating room (OR) as an inpatient
over half the time, while EVI was carried out as an outpatient 75%
of the time and predominantly in the radiology suite. This method
of data presentation not only blurs important financial differences
from one hospital to another but also misses an opportunity to
define “best practices” derived from one institution over another.
Hospital revenue. The authors of this study included few
details on revenue and, for example, they failed to provide the
proportion of patients with chronic comorbidities (DRG #553)
and the specific net revenue for this group. Under CMS reimburse-
ment, these secondary diagnoses can provide additional revenue
for an inpatient procedure, which could account for a $4000 to
$5000 difference in reimbursement for an individual case (vs DRG
#554) and obviously influence contribution margin. Outpatient
reimbursements (APC) under CMS are based on individual en-
counters, so that multiple components for more than one service
provided on the same day can be summated for that hospital visit.
For example, crossing a chronic total occlusion to perform a
balloon angioplasty with placement of a stent in the contralateral
common iliac artery is a compilation of six CPT/HCPS codes of
which 37205 (transcatheter placement of an intravascular stent)
accounts for more than one half of the $7577 estimated total
payment. It is imperative that the hospital coders bill for every
component of the service to maximize revenue.
Hospital costs. A disproportionately high proportion (46%)
of EVI was performed in an OR setting, which was related to lack
of access to interventional suites by the surgeons, who performed
the majority of these procedures. As a former Academic Medicalquences as a cautionary tale for hospital administrators, who nego-
tiate separate, exclusive relationships with interventional radiolo-
gists or cardiologists regarding space—these specialists do not own
the interventional suites, they just use hospital space. The surgeon
is forced to use the OR where the cost structure is significantly
higher than that of the radiology suite, because of the higher cost
per minute of an OR vs a radiology suite (space costs) and the
greater number/payment rate of OR personnel. When inpatient
status (38%) is combined with an OR site, inpatient hospital costs
($12,278) are twice that of procedures performed as an outpatient.
Ironically, this inpatient figure for the less invasive EVI is compa-
rable to that for the surgical treatment of a claudication patient
adjusted for inflation to 2005 reported previously by us.3
Although, unfortunately, no individual components of inpa-
tient/outpatient costs are provided,3 obviously device cost was a
prime driver of the total cost of EVI and poor contributionmargins
in this present study. The use of stents (45%) or atherectomy
devices (38%) doubled the direct cost of the procedure, while
multiple stents further escalated the cost. As opposed to the
situation with open vascular surgery where modification of physi-
cian practice helps to reduce the prime drivers of cost-length of
stay, the hospital runs up against the fixed purchase price of the
device, which has been shown in other studies with endovascular
aneurysm repair to negatively influence hospital profit margin.
Finally, level I evidence with appropriate clinical outcomes rather
than the surrogate outcome of patency are conflicting on the
efficacy of stents over PTA, particularly in the femoral popliteal
segment, so that no grade A recommendation can be made.
Justification for the use of atherectomy catheters is even more
murky and clouded by level 5 studies, many of which are con-
ducted by physician advocates and, in some instances, by those
with direct financial interest in the product. The introduction of
new and potentially costly technology into a hospital should be
guided by evidence for its clinical effectiveness and therefore
appropriate use.
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